Fate Therapeutics Seals Deal With JNJ For Cancer Immunotherapies, Stock Jumps

(RTTNews) - Shares of Fate Therapeutics Inc. (FATE) were up over 20 percent in extended trading on Thursday, following a worldwide collaboration with Johnson & Johnson subsidiary (JNJ) Janssen for novel induced pluripotent stem cell-derived cell-based cancer immunotherapies.

Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen-binding domains for up to four tumor-associated antigen targets while Fate Therapeutics will apply its proprietary induced pluripotent stem cell (iPSC) product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.

Fate Therapeutics is eligible to receive $50 million upfront payment and $50 million equity investment through the sale of its newly issued shares at a price of $31.00 per share to Johnson & Johnson Innovation - JJDC, the corporate venture capital arm of Johnson & Johnson.

The Company is also entitled to receive payments of up to $1.8 billion in development and regulatory milestones and up to $1.2 billion in commercial milestone payments, plus double-digit royalties, from Janssen.

Commenting on the deal, Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics, said, "The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssen's proprietary antigen-binding domains, while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies."

FATE closed Thursday's trading at $21.07, up 4.26%. In after-hours, the stock soared 23.40% to $26.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.